Published in Arch Neurol on February 01, 2007
Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology (2014) 2.64
Review. The neurobiology of pathological gambling and drug addiction: an overview and new findings. Philos Trans R Soc Lond B Biol Sci (2008) 2.40
Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain (2009) 2.35
Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc (2009) 2.06
Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord (2009) 1.89
Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity. Psychopharmacology (Berl) (2011) 1.77
Decision-making during gambling: an integration of cognitive and psychobiological approaches. Philos Trans R Soc Lond B Biol Sci (2010) 1.46
Pathological gambling: prevalence, diagnosis, comorbidity, and intervention in Germany. Dtsch Arztebl Int (2012) 1.41
Clarifying the role of personality dispositions in risk for increased gambling behavior. Pers Individ Dif (2008) 1.32
The roles of dopamine and serotonin in decision making: evidence from pharmacological experiments in humans. Neuropsychopharmacology (2010) 1.28
Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord (2008) 1.27
Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat (2008) 1.19
Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease. Mov Disord (2010) 1.17
Impulse control disorders in Parkinson's disease: recent advances. Curr Opin Neurol (2011) 1.11
Parkinson's disease-related disorders in the impulsive-compulsive spectrum. J Neurol (2008) 1.08
Impulse control disorders in Parkinson's disease: seeking a roadmap toward a better understanding. Brain Struct Funct (2011) 0.97
Stroop test performance in impulsive and non impulsive patients with Parkinson's disease. Parkinsonism Relat Disord (2011) 0.97
Deep brain stimulation of nucleus accumbens region in alcoholism affects reward processing. PLoS One (2012) 0.97
Personality traits in patients with Parkinson's disease: assessment and clinical implications. J Neurol (2011) 0.96
Cognitive status of patients with Parkinson's disease and pathological gambling. J Neurol (2009) 0.96
Impulse control disorders following deep brain stimulation of the subthalamic nucleus in Parkinson's disease: clinical aspects. Parkinsons Dis (2011) 0.96
The temptation of suicide: striatal gray matter, discounting of delayed rewards, and suicide attempts in late-life depression. Psychol Med (2011) 0.95
Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics (2008) 0.94
Financial and psychological risk attitudes associated with two single nucleotide polymorphisms in the nicotine receptor (CHRNA4) gene. PLoS One (2009) 0.93
Serotonin and dopamine play complementary roles in gambling to recover losses. Neuropsychopharmacology (2010) 0.93
Pramipexole and compulsive masturbation. Psychiatry (Edgmont) (2007) 0.91
Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol (2011) 0.89
Prospective cohort study of impulse control disorders in Parkinson's disease. Mov Disord (2013) 0.88
Dopamine-induced nonmotor symptoms of Parkinson's disease. Parkinsons Dis (2011) 0.88
Impulsivity and apathy in Parkinson's disease. J Neuropsychol (2013) 0.87
Novelty seeking behaviour in Parkinson's disease. Neuropsychologia (2011) 0.86
Salivary cortisol levels in Parkinson's disease and its correlation to risk behaviour. J Neurol Neurosurg Psychiatry (2011) 0.86
Targeting impulsivity in Parkinson's disease using atomoxetine. Brain (2014) 0.84
Impulse control disorders in Parkinson's disease: the role of personality and cognitive status. J Neurol (2012) 0.83
The role of dopamine in risk taking: a specific look at Parkinson's disease and gambling. Front Behav Neurosci (2014) 0.83
Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders. J Neurol (2010) 0.82
Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists. J Clin Neurosci (2010) 0.82
Impulsive and compulsive behaviors in Parkinson's disease. Annu Rev Clin Psychol (2013) 0.82
Impulsive and compulsive behaviors in Parkinson's disease. Front Aging Neurosci (2014) 0.82
Dopamine receptors and Parkinson's disease. Int J Med Chem (2011) 0.81
Nonmotor Features in Parkinson's Disease: What Are the Most Important Associated Factors? Parkinsons Dis (2016) 0.80
Pathological gambling and dopamine agonists: A phenotype? Neuropsychiatr Dis Treat (2007) 0.80
Altruistic punishment in patients with Parkinson's disease with and without impulsive behaviour. Neuropsychologia (2010) 0.80
Diagnosis and treatment of impulse control disorders in patients with movement disorders. Ther Adv Neurol Disord (2013) 0.80
Gambling disorder during dopamine replacement treatment in Parkinson's disease: a comprehensive review. Biomed Res Int (2014) 0.80
Impulse control disorders in Parkinson's disease: an overview from neurobiology to treatment. J Neurol (2014) 0.79
The impact of subthalamic deep brain stimulation on caregivers of Parkinson's disease patients: an exploratory study. J Neurol (2014) 0.79
Impulse control disorders in Parkinson's disease: background and update on prevention and management. Neurodegener Dis Manag (2012) 0.79
Ventral striatal dopamine synthesis capacity predicts financial extravagance in Parkinson's disease. Front Psychol (2013) 0.79
Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review. J Clin Psychopharmacol (2016) 0.76
Altered striatal circuits underlie characteristic personality traits in Parkinson's disease. J Neurol (2016) 0.76
Maladaptive reward-learning and impulse control disorders in patients with Parkinson's disease: a clinical overview and pathophysiology update. J Mov Disord (2014) 0.76
Probing the Role of Medication, DBS Electrode Position, and Antidromic Activation on Impulsivity Using a Computational Model of Basal Ganglia. Front Hum Neurosci (2016) 0.76
Impulsivity is Associated with Increased Metabolism in the Fronto-Insular Network in Parkinson's Disease. Front Behav Neurosci (2015) 0.75
Dopaminergic and clinical correlates of pathological gambling in Parkinson's disease: a case report. Front Behav Neurosci (2013) 0.75
Trait Impulsivity and Anhedonia: Two Gateways for the Development of Impulse Control Disorders in Parkinson's Disease? Front Psychiatry (2016) 0.75
Impulsive behavior and associated clinical variables in Parkinson's disease. Psychosomatics (2011) 0.75
Publicity and reports of behavioral addictions associated with dopamine agonists. J Behav Addict (2015) 0.75
Pathological gambling in Parkinson's disease: what are the risk factors and what is the role of impulsivity? Eur J Neurosci (2016) 0.75
Deep-Brain Stimulation of the Subthalamic Nucleus Selectively Decreases Risky Choice in Risk-Preferring Rats. eNeuro (2017) 0.75
Chronic administration of the dopamine D2/3 agonist ropinirole invigorates performance of a rodent slot machine task, potentially indicative of less distractible or compulsive-like gambling behaviour. Psychopharmacology (Berl) (2016) 0.75
Dopamine dysregulation syndrome. Hypothetical application of reward system stimulation for the treatment of anhedonia in Parkinson's disease patients. J Neurol (2008) 0.75
Associations of specific psychiatric disorders with isolated focal dystonia, and monogenic and idiopathic Parkinson's disease. J Neurol (2017) 0.75
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15
Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice. Nat Genet (2013) 2.62
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology (2012) 2.34
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Short and long latency afferent inhibition in Parkinson's disease. Brain (2003) 2.02
Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg (2003) 2.01
Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol (2007) 2.01
Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol (2004) 2.00
Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98
Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology (2012) 1.91
Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord (2007) 1.82
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol (2013) 1.81
Psychogenic movement disorders. Curr Opin Neurol (2009) 1.81
Overview of the extranigral aspects of Parkinson disease. Arch Neurol (2009) 1.79
Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol (2010) 1.77
Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol (2011) 1.73
Premotor Parkinson's disease: concepts and definitions. Mov Disord (2012) 1.70
Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord (2011) 1.66
Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol (2011) 1.65
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. J Neurosurg (2011) 1.63
Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63
Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol (2004) 1.63
Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol (2009) 1.62
Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. J Neurosurg (2002) 1.60
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord (2008) 1.59
Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. Ann Neurol (2013) 1.58
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord (2006) 1.54
Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord (2004) 1.54
Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry (2012) 1.54
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain (2006) 1.53
Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. Mov Disord (2009) 1.53
Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology (2009) 1.51
Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors. Brain (2004) 1.47
Dystonia as a presenting sign of spinocerebellar ataxia type 1. Mov Disord (2004) 1.46
Long-term hardware-related complications of deep brain stimulation. Neurosurgery (2002) 1.46
Motor cortical stimulation for parkinsonism in multiple system atrophy. Arch Neurol (2003) 1.45
Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease? Mov Disord (2008) 1.45
Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. Neurology (2014) 1.45
The fragile X premutation presenting as essential tremor. Arch Neurol (2003) 1.43
α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol (2012) 1.42
Subthalamic nucleus stimulation: improvements in outcome with reprogramming. Arch Neurol (2006) 1.42
Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord (2013) 1.42
Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol (2002) 1.40
Reporting clinical trials: full access to all of the data. Arch Neurol (2002) 1.39
Definition and classification of hyperkinetic movements in childhood. Mov Disord (2010) 1.38
Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol (2002) 1.36
Medication-related impulse control and repetitive behaviors in Parkinson's disease. Curr Opin Neurol (2007) 1.35
Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol (2006) 1.34
Investigation of c9orf72 in 4 neurodegenerative disorders. Arch Neurol (2012) 1.32
Gait abnormalities in psychogenic movement disorders. Mov Disord (2007) 1.32
Cortical and spinal abnormalities in psychogenic dystonia. Ann Neurol (2006) 1.31
Apraxia in movement disorders. Brain (2005) 1.29
The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. Hum Mol Genet (2004) 1.29
Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol (2004) 1.28
The nonmotor symptoms of Parkinson's disease--an overview. Mov Disord (2010) 1.25
Movement disorders on YouTube--caveat spectator. N Engl J Med (2011) 1.25
Impulse control and related disorders in Parkinson's disease: review. Ann N Y Acad Sci (2008) 1.24